

NYRx Drug Class Coverage Overview

Short-Acting Opioids

Drugs in the Short-Acting Opioids drug class are included on the [NYRx Preferred Drug List](#) and are subject to prior authorization (PA) requirements of the [Drug Utilization Review Program](#) (DUR):

Preferred Drugs	Non-Preferred Drugs	Prior Authorization/Coverage Parameters
I. Analgesics		
Opioids – Short-Acting^{CC}		
butalbital/APAP/caffeine/codeine codeine codeine/APAP hydrocodone/APAP hydrocodone/ibuprofen morphine IR oxycodone/APAP tramadol tablet	Apadaz [®] benzhydrocodone/APAP butalbital compound/codeine butorphanol nasal spray dihydrocodeine/APAP/caffeine Dilaudid [®] hydromorphone levorphanol meperidine Nalocet [®] Nucynta [®] ST oxycodone oxymorphone pentazocine/naloxone Percocet [®] Prolate [®] solution, tablet Roxicodone [®] Seglentis [®] tramadol solution tramadol/APAP	CLINICAL CRITERIA (CC) * <ul style="list-style-type: none"> Limited to a total of 4 opioid prescriptions every 30 days. Initial prescription for opioid-naïve patients limited to a 7-day supply. PA required for initiation of opioid therapy for patients on established opioid dependence therapy. PA required for use if ≥ 90 MME of opioid per day for management of non-acute pain (> 7 days) <ul style="list-style-type: none"> Exception for diagnosis of cancer or sickle cell disease, or hospice program PA is required for opioid-naïve patients for prescription requests ≥ 50 MME per day. PA required for continuation of opioid therapy beyond an initial 7-day supply in patients established on gabapentin or pregabalin PA required for initiation of opioid therapy in patients currently on benzodiazepine therapy PA required for any codeine- or tramadol-containing products in pts < 12 years PA required for initiation of opioid therapy for patients on > 7 days established CNS stimulant therapy STEP THERAPY (ST) <ul style="list-style-type: none"> Nucynta[®] (tapentadol IR) – Trial with tramadol and 1 preferred opioid before tapentadol immediate-release (IR) For Non-opioid Pain management alternatives please visit: https://health.ny.gov/health_care/medicaid/program/opioid_management/docs/non_opioid_alternatives_to_pain_management.pdf <p><small>*Exemptions from requirements for diagnosis of cancer, sickle cell disease, or hospice care</small></p>

Prior Authorization Requirements

- Preferred drugs will not require PA if the required coverage parameters are found in the member’s Medicaid claim history at the time of pharmacy claim submission and if clinical criteria are met as outlined in the PDL. Non-preferred drugs will require PA.
- Clinical Criteria requirements outlined in the PDL are in response to NYS legislation, regulation, policy and/or CDC guidance, for example:
 - Initial opioid prescribing for acute pain is [limited to a seven-day supply](#) per New York State Public Health Law

- PA is required for prescriptions of opioid analgesics in excess of [four prescriptions in a thirty-day period](#).
- The MME limits are based on [CDC Clinical Practice Guidelines](#).

What Pharmacy Providers Need to Do

Pharmacy providers should become familiar with the Short-Acting Opioid coverage criteria and the [NYRx Preferred Drug List](#) and incorporate this information when discussing the need for PA with prescribers.

What Prescribers Need to Do

Prescribers should become familiar with the Short-Acting Opioid coverage criteria and the [NYRx Preferred Drug List](#) and incorporate this information when prescribing for Medicaid members.

Resources

- [CDC's Clinical Practice Guideline for Prescribing Opioids for Pain](#)
- [NYRx Education & Outreach Website](#)
- [NYRx Preferred Drug List](#)
- [NYRx Prior Authorization Call and Fax Guide](#)
- [NYS DOH Opioid Management Resources](#)

Contact Information

The NYRx E&O Call Center is available at 833-967-7310 from 8:00 AM to 5:00 PM ET, Monday through Friday, excluding holiday and via email at NYRxEO@magellanhealth.com

The Education and Outreach team hosts virtual office hours every week for stakeholders to ask questions related to NYRx and care coordination. Visit the [NYRx Education & Outreach Website](#) for more information.